Canopus BioPharma Incorporated ' Product Pipeline Review ' 2012

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Canopus BioPharma Incorporated ' Product Pipeline Review ' 2012
Published on December 2012

Report Summary


Summary

Global Market Direct's pharmaceuticals report, "Canopus BioPharma Incorporated - Product Pipeline Review - 2012" provides data on
the Canopus BioPharma Incorporated's research and development focus. The report includes information on current developmental
pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Canopus BioPharma
Incorporated's corporate website, SEC filings, investor presentations and featured press releases, both from Canopus BioPharma
Incorporated and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- Canopus BioPharma Incorporated - Brief Canopus BioPharma Incorporated overview including business description, key information
and facts, and its locations and subsidiaries.
- Review of current pipeline of Canopus BioPharma Incorporated human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities,
across the globe.
- Product profiles for late stage and clinical stage products of Canopus BioPharma Incorporated with complete description of the
product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Canopus BioPharma Incorporated's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Canopus BioPharma Incorporated's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Canopus BioPharma Incorporated in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Canopus BioPharma Incorporated's R&D portfolio and develop key strategic
initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Canopus BioPharma Incorporated.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Canopus BioPharma Incorporated and identify potential opportunities in those
areas.

Canopus BioPharma Incorporated ' Product Pipeline Review ' 2012 (From Slideshare) Page 1/6


Table of Content

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Canopus BioPharma Incorporated Snapshot 5
Canopus BioPharma Incorporated Overview 5
Key Information 5
Key Facts 5
Canopus BioPharma Incorporated ' Research and Development Overview 6
Key Therapeutic Areas 6
Canopus BioPharma Incorporated ' Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products ' Monotherapy 10
Canopus BioPharma Incorporated ' Pipeline Products Glance 11
Canopus BioPharma Incorporated Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Canopus BioPharma Incorporated ' Early Stage Pipeline Products 12
Pre-Clinical Products/Combination Treatment Modalities 12
Discovery Products/Combination Treatment Modalities 13
Canopus BioPharma Incorporated ' Drug Profiles 14
CB-1922 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
CB-2009 15
R&D Progress 15
CB-2029 16
R&D Progress 16
CB-2030 17
R&D Progress 17
CB-3900 18
R&D Progress 18
CB-4500 19
R&D Progress 19



CB-5300 20
R&D Progress 20
oltipraz 22
R&D Progress 22
Zofroxia 23
R&D Progress 23
Canopus BioPharma Incorporated ' Pipeline Analysis 24
Canopus BioPharma Incorporated ' Pipeline Products by Therapeutic Class 24
Canopus BioPharma Incorporated ' Pipeline Products by Route of Administration 25
Canopus BioPharma Incorporated ' Pipeline Products By Mechanism of Action 26
Canopus BioPharma Incorporated - Dormant Projects 27
Canopus BioPharma Incorporated ' Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Financial Deals Landscape 29
Canopus BioPharma Incorporated, Deals Summary 29
Canopus BioPharma Incorporated, Pharmaceuticals & Healthcare, Deal Details 30
Partnerships 30
Canopus BioPharma Enters Into Co-Development Agreement With Chinese Researcher 30
Licensing Agreements 31
Canopus BioPharma Enters Into Licensing Agreement With Office Of Disease Control And Emergency Response, CDC And SFDA 31
Canopus BioPharma Enters Into Licensing Agreement With WARF 32
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 34
Disclaimer 34

List of Tables

Canopus BioPharma Incorporated, Key Information 5
Canopus BioPharma Incorporated, Key Facts 5
Canopus BioPharma Incorporated ' Pipeline by Indication, 2012 8
Canopus BioPharma Incorporated ' Pipeline by Stage of Development, 2012 9
Canopus BioPharma Incorporated ' Monotherapy Products in Pipeline, 2012 10
Canopus BioPharma Incorporated ' Phase II, 2012 11
Canopus BioPharma Incorporated ' Pre-Clinical, 2012 12



Canopus BioPharma Incorporated ' Discovery, 2012 13
Canopus BioPharma Incorporated ' Pipeline By Therapeutic Class, 2012 24
Canopus BioPharma Incorporated ' Pipeline By Route of Administration, 2012 25
Canopus BioPharma Incorporated ' Pipeline Products By Mechanism of Action, 2012 26
Canopus BioPharma Incorporated - Dormant Developmental Projects,2012 27
Canopus BioPharma Incorporated, Other Locations 28
Canopus BioPharma Incorporated, Deals Summary 29
Canopus BioPharma Enters Into Co-Development Agreement With Chinese Researcher 30
Canopus BioPharma Enters Into Licensing Agreement With Office Of Disease Control And Emergency Response, CDC And SFDA 31
Canopus BioPharma Enters Into Licensing Agreement With WARF 32

List of Figures

Canopus BioPharma Incorporated ' Pipeline by Indication, 2012 7
Canopus BioPharma Incorporated ' Pipeline by Stage of Development, 2012 9
Canopus BioPharma Incorporated ' Monotherapy Products in Pipeline, 2012 10
Canopus BioPharma Incorporated ' Pipeline By Therapeutic Class, 2012 24
Canopus BioPharma Incorporated ' Pipeline By Route of Administration, 2012 25
Canopus BioPharma Incorporated - Pipeline Products By Mechanism of Action, 2012 26


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 1 500.00 Quantity: _____

Site License--USD 3 000.00 Quantity: _____

Corporate License--USD 4 500.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Canopus BioPharma Incorporated ' Product Pipeline Review ' 2012

Recomendados

Recomendados

Más contenido relacionado

Destacado

Destacado (18)

Más de ReportLinker.com

Más de ReportLinker.com (20)

Canopus BioPharma Incorporated ' Product Pipeline Review ' 2012